Dexcom (DXCM) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DXCM Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$1,868.22

▲(22.19% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $1,868.22 with a high forecast of $2,265.86 and a low forecast of $1,604.98. The average price target represents a 22.19% change from the last price of $1,529.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1130":"$1,130","1414":"$1,414","1698":"$1,698","1982":"$1,982","2266":"$2,266"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2265.8610276,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.27K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1868.22463158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.87K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1604.98489455,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1130,1414,1698,1982,2266],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1536.29,1592.410848276923,1648.5316965538461,1704.652544830769,1760.7733931076923,1816.8942413846153,1873.0150896615385,1929.1359379384614,1985.2567862153846,2041.3776344923076,2097.4984827692306,2153.619331046154,2209.740179323077,{"y":2265.8610276,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1536.29,1561.8234331984615,1587.3568663969231,1612.8902995953845,1638.423732793846,1663.9571659923076,1689.4905991907692,1715.0240323892308,1740.5574655876924,1766.090898786154,1791.6243319846153,1817.157765183077,1842.6911983815385,{"y":1868.22463158,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1536.29,1541.5742226576922,1546.8584453153846,1552.1426679730769,1557.4268906307693,1562.7111132884615,1567.9953359461538,1573.2795586038462,1578.5637812615385,1583.8480039192307,1589.1322265769231,1594.4164492346154,1599.7006718923078,{"y":1604.98489455,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1234.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1131.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1169,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1213,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1310,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1243,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1209.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1209.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1241.72,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1241.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1430,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1529,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1536.29,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$2,266

Average Price Target$1,868

Lowest Price Target$1,605

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$2,077.04

Buy

35.84%

Upside

Reiterated

10/30/26

Dexcom (DXCM) Receives a Buy from Evercore ISI

Jayson Bedford

Raymond James

$1,774.92→$1,831.57

Buy

19.79%

Upside

Reiterated

10/30/26

DexCom price target raised to $97 from $94 at Raymond JamesDexCom price target raised to $97 from $94 at Raymond James

Robbie Marcus

J.P. Morgan

$1,548.34→$1,604.98

Hold

4.97%

Upside

Assigned

10/30/26

DexCom price target raised to $85 from $82 at JPMorganDexCom price target raised to $85 from $82 at JPMorgan

Christopher Pasquale

Barclays

$2,171.45→$2,265.86

Buy

48.19%

Upside

Reiterated

10/30/26

Dexcom (DXCM) Receives a Buy from Barclays

Josh Jennings

TD Cowen

$1,793.81

Buy

17.32%

Upside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), PTC Therapeutics (NASDAQ: PTCT) and Dexcom (NASDAQ: DXCM)

William Plovanic

Canaccord Genuity

$1,699.4→$1,831.57

Buy

19.79%

Upside

Reiterated

10/30/26

DexCom price target raised to $97 from $90 at CanaccordDexCom price target raised to $97 from $90 at Canaccord

Jonathan Block

Stifel Nicolaus

$1,793.81

Buy

17.32%

Upside

Reiterated

10/30/26

Stifel Nicolaus Reaffirms Their Buy Rating on Dexcom (DXCM)

Danielle Antalffy

UBS

$1,925.98→$2,020.39

Buy

32.14%

Upside

Assigned

10/30/26

UBS Remains a Buy on Dexcom (DXCM)

Matthew O'Brien

Piper Sandler

$1,793.81

Buy

17.32%

Upside

Reiterated

10/30/26

Dexcom (DXCM) Receives a Buy from Piper Sandler

Kendall Au

RBC Capital

$1,982.63

Buy

29.67%

Upside

Reiterated

10/29/26

RBC Capital Remains a Buy on Dexcom (DXCM)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$1,774.92→$1,642.75

Buy

7.44%

Upside

Assigned

10/27/26

Dexcom (DXCM) Receives a Buy from Leerink Partners

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

10/23/26

Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Oric Pharmaceuticals (ORIC)

Joanne Wuensch

Citi

$1,982.63

Buy

29.67%

Upside

Reiterated

10/21/26

Citi Sticks to Its Buy Rating for Dexcom (DXCM)

Larry Biegelsen

Wells Fargo

$1,699.4

Buy

11.14%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA) and Dexcom (NASDAQ: DXCM)

Anthony Petrone

Mizuho Securities

$1,793.81→$1,888.22

Buy

23.49%

Upside

Assigned

10/13/26

DexCom price target raised to $100 from $95 at MizuhoDexCom price target raised to $100 from $95 at Mizuho

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$2,077.04

Buy

35.84%

Upside

Reiterated

10/30/26

Dexcom (DXCM) Receives a Buy from Evercore ISI

Jayson Bedford

Raymond James

$1,774.92→$1,831.57

Buy

19.79%

Upside

Reiterated

10/30/26

DexCom price target raised to $97 from $94 at Raymond JamesDexCom price target raised to $97 from $94 at Raymond James

Robbie Marcus

J.P. Morgan

$1,548.34→$1,604.98

Hold

4.97%

Upside

Assigned

10/30/26

DexCom price target raised to $85 from $82 at JPMorganDexCom price target raised to $85 from $82 at JPMorgan

Christopher Pasquale

Barclays

$2,171.45→$2,265.86

Buy

48.19%

Upside

Reiterated

10/30/26

Dexcom (DXCM) Receives a Buy from Barclays

Josh Jennings

TD Cowen

$1,793.81

Buy

17.32%

Upside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK), PTC Therapeutics (NASDAQ: PTCT) and Dexcom (NASDAQ: DXCM)

William Plovanic

Canaccord Genuity

$1,699.4→$1,831.57

Buy

19.79%

Upside

Reiterated

10/30/26

DexCom price target raised to $97 from $90 at CanaccordDexCom price target raised to $97 from $90 at Canaccord

Jonathan Block

Stifel Nicolaus

$1,793.81

Buy

17.32%

Upside

Reiterated

10/30/26

Stifel Nicolaus Reaffirms Their Buy Rating on Dexcom (DXCM)

Danielle Antalffy

UBS

$1,925.98→$2,020.39

Buy

32.14%

Upside

Assigned

10/30/26

UBS Remains a Buy on Dexcom (DXCM)

Matthew O'Brien

Piper Sandler

$1,793.81

Buy

17.32%

Upside

Reiterated

10/30/26

Dexcom (DXCM) Receives a Buy from Piper Sandler

Kendall Au

RBC Capital

$1,982.63

Buy

29.67%

Upside

Reiterated

10/29/26

RBC Capital Remains a Buy on Dexcom (DXCM)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$1,774.92→$1,642.75

Buy

7.44%

Upside

Assigned

10/27/26

Dexcom (DXCM) Receives a Buy from Leerink Partners

Travis Steed

Bank of America Securities

―

Buy

―

Reiterated

10/23/26

Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Oric Pharmaceuticals (ORIC)

Joanne Wuensch

Citi

$1,982.63

Buy

29.67%

Upside

Reiterated

10/21/26

Citi Sticks to Its Buy Rating for Dexcom (DXCM)

Larry Biegelsen

Wells Fargo

$1,699.4

Buy

11.14%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA) and Dexcom (NASDAQ: DXCM)

Anthony Petrone

Mizuho Securities

$1,793.81→$1,888.22

Buy

23.49%

Upside

Assigned

10/13/26

DexCom price target raised to $100 from $95 at MizuhoDexCom price target raised to $100 from $95 at Mizuho

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AORTArtivion

MDWDMediwound

IMUXImmunic

RZLTRezolute

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

3 Months

Danielle AntalffyUBS

Success Rate

22/34 ratings generated profit

Average Return

+3.06%

Copying Danielle Antalffy's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +3.06% per trade.

1 Year

Steven LichtmanWilliam Blair

Success Rate

35/50 ratings generated profit

Average Return

+35.83%

Copying Steven Lichtman's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +35.83% per trade.

2 Years

Steven LichtmanWilliam Blair

Success Rate

37/50 ratings generated profit

Average Return

+83.24%

Copying Steven Lichtman's trades and holding each position for 2 Years would result in 74.00% of your transactions generating a profit, with an average return of +83.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DXCM has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DXCM average Analyst price target in the past 3 months is 1,868.22.

Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $13.47 with a range of $12.59 to $14.48. The previous quarter’s EPS was $13.71. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $26.01B with a range of $25.58B to $26.51B. The previous quarter’s sales results were $25.26B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Stock Forecast FAQ

What is MX:DXCM’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 1,868.22.

What is MX:DXCM’s upside potential, based on the analysts’ average price target?

Dexcom has 22.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Dexcom a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy, which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Dexcom’s share price target?

The average share price target for Dexcom is 1,868.22. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $2,265.86 ,and the lowest forecast is $1,604.98. The average share price target represents 22.19% Increase from the current price of $1,529.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Dexcom?

To buy shares of MX:DXCM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Dexcom (DXCM) Stock Forecast & Price Target

DXCM Analyst Ratings

DXCM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DXCM Analyst Recommendation Trends

DXCM Financial Forecast

DXCM Earnings Forecast

DXCM Sales Forecast

DXCM Stock Forecast FAQ

Detailed List of Analyst Forecasts